Page 41 - Demo

pathways by fenfluramine. Science, 2002. 297(5581):p. 609-11, DOI: 10.1126/science.1072327.68. Yamashita, M., et al., Expression cloning of a cDNAencoding the bovine histamine H1 receptor. Proc NatlAcad Sci U S A, 1991. 88(24): p. 11515-9, DOI:10.1073/pnas.88.24.11515.69. He, M., C. Deng, and X.F. Huang, The role ofhypothalamic H1 receptor antagonism inantipsychotic-induced weight gain. CNS Drugs, 2013.27(6): p. 423-34, DOI: 10.1007/s40263-013-0062-1.70. Tecott, L.H., et al., Eating disorder and epilepsy in micelacking 5-HT2c serotonin receptors. Nature, 1995.374(6522): p. 542-6, DOI: 10.1038/374542a0.71. Sakata, T., H. Yoshimatsu, and M. Kurokawa,Hypothalamic neuronal histamine: implications of itshomeostatic control of energy metabolism. Nutrition,1997. 13(5):p. 403-11.72. Makki, K., P. Froguel, and I. Wolowczuk, Adipose tissuein obesity-related inflammation and insulinresistance: cells, cytokines, and chemokines. ISRNInflamm, 2013. 2013: p. 139239, DOI:10.1155/2013/139239.73. Ryan, A.S., et al., Plasma adiponectin and leptin levels,body composition, and glucose utilization in adultwomen with wide ranges of age and obesity. DiabetesCare, 2003. 26(8): p. 2383-8.74. Sugai, T., et al., Dysregulation of adipocytokines relatedto second-generation antipsychotics in normal fastingglucose patients with schizophrenia. J ClinPsychopharmacol, 2012. 32(3): p. 390-3, DOI:10.1097/JCP.0b013e3182524393.75. Fantuzzi, G., Adiponectin in inflammatory and immunemediated diseases. Cytokine, 2013. 64(1): p. 1-10,DOI: 10.1016/j.cyto.2013.06.317.76. Robinson, K., J. Prins, and B. Venkatesh, Clinical revieadiponectin biology and its role in inflammation andcritical illness. Crit Care, 2011. 15(2): p. 221, DOI:10.1186/cc10021.77. Lira, F.S., et al., Both adiponectin and interleukin-10inhibit LPS-induced activation of the NF-kappaBpathway in 3T3-L1 adipocytes. Cytokine, 2012. 57(1):p. 98-106, DOI: 10.1016/j.cyto.2011.10.001.78. Gastaldelli, A., M. Gaggini, and R.A. DeFronzo, Role ofAdipose Tissue Insulin Resistance in the NaturalHistory of Type 2 Diabetes: Results From the SanAntonio Metabolism Study. Diabetes, 2017. 66(4): p.815-822, DOI: 10.2337/db16-1167.79. Harvey, P.D. and C.R. Bowie, Ziprasidone: efficacy,tolerability, and emerging data on wide-rangingeffectiveness. Expert Opin Pharmacother, 2005. 6(2):p. 337-46, DOI: 10.1517/14656566.6.2.337.80. Hunter, S.J. and W.T. Garvey, Insulin action and insulinresistance: diseases involving defects in insulinreceptors, signal transduction, and the glucosetransport effector system. Am J Med, 1998. 105(4): p.331-45.81. Smith, G.C., et al., Atypical antipsychotic drugs inducederangements in glucose homeostasis by acutelyincreasing glucagon secretion and hepatic glucoseoutput in the rat. Diabetologia, 2008. 51(12): p. 2309-82. Robinson, K.A., S.Z. Yacoub Wasef, and M.G. Buse, Attherapeutic concentrations, olanzapine does not52. Hemmrich, K., et al., Clozapine enhances differentiationof adipocyte progenitor cells. Mol Psychiatry, 2006.11(11): p. 980-1, DOI: 10.1038/sj.mp.4001892.53. Newcomer, J.W., Second-generation (atypical)antipsychotics and metabolic effects: a comprehensiveliterature review. CNS Drugs, 2005. 19 Suppl 1: p. 1-93, DOI: 10.2165/00023210-200519001-00001.54. Allison, D.B., et al., Antipsychotic-induced weight gain:a comprehensive research synthesis. Am J Psychiatry,1999. 156(11): p. 1686-96, DOI:10.1176/ajp.156.11.1686.55. Wang, Y., et al., Pimozide, a novel fatty acid bindingprotein 4 inhibitor, promotes adipogenesis of 3T3-L1cells by activating PPARgamma. ACS Chem Neurosci,2015. 6(2): p. 211-8, DOI: 10.1021/cn5002107.56. Pavan, C., et al., Weight gain related to treatment withatypical antipsychotics is due to activation of PKCbeta. Pharmacogenomics J, 2010. 10(5): p. 408-17,DOI: 10.1038/tpj.2009.67.57. Nimura, S., et al., Olanzapine promotes the accumulationof lipid droplets and the expression of multipleperilipins in human adipocytes. Biochem Biophys ResCommun, 2015. 467(4): p. 906-12, DOI:10.1016/j.bbrc.2015.10.045.58. Qiao, L., et al., Transcriptional regulation of fatty acidtranslocase/CD36 expression by CCAAT/enhancerbinding protein alpha. J Biol Chem, 2008. 283(14): p.8788-95, DOI: 10.1074/jbc.M800055200.59. Saini, N., et al., Fatty acid transport protein-2 inhibitorGrassofermata/CB5 protects cells against lipidaccumulation and toxicity. Biochem Biophys ResCommun, 2015. 465(3): p. 534-41, DOI:10.1016/j.bbrc.2015.08.055.60. Hotamisligil, G.S., Inflammation, metaflammation andimmunometabolic disorders. Nature, 2017. 542(7640):p. 177-185, DOI: 10.1038/nature21363.61. Yamauchi, T. and T. Kadowaki, Physiological andpathophysiological roles of adiponectin andadiponectin receptors in the integrated regulation ofmetabolic and cardiovascular diseases. Int J Obes(Lond), 2008. 32 Suppl 7: p. S13-8, DOI:10.1038/ijo.2008.233.62. Trujillo, M.E. and P.E. Scherer, Adiponectin%u2014journey froman adipocyte secretory protein to biomarker of themetabolic syndrome. J Intern Med, 2005. 257(2): p.167- 75, DOI: 10.1111/j.1365-2796.2004.01426.x.63. Sarvari, A.K., et al., Atypical antipsychotics induce bothproinflammatory and adipogenic gene expression inhuman adipocytes in vitro. Biochem Biophys ResCommun, 2014. 450(4): p. 1383-9, DOI:10.1016/j.bbrc.2014.07.005.64. Tsubai, T., et al., Effects of clozapine on adipokinesecretions/productions and lipid droplets in 3T3-L1adipocytes. J Pharmacol Sci, 2017. 133(2): p. 79-87,DOI: 10.1016/j.jphs.2017.01.004.65. Friedman, J.M. and J.L. Halaas, Leptin and the regulationof body weight in mammals. Nature, 1998. 395(6704):p. 763-70, DOI: 10.1038/27376.66. Heymsfield, S.B., et al., Recombinant leptin for weightloss in obese and lean adults: a randomized,controlled, dose-escalation trial. JAMA, 1999.282(16): p. 1568-75.67. Heisler, L.K., et al., Activation of central melanocortin40ANALESRANFwww.analesranf.comSecond-generation antipsychotic drugs and their impact onadipose tissuePatricia Rada, V%u00edtor Ferreira y %u00c1ngela M. ValverdeAn. R. Acad. Farm.Vol. 90. n%u00ba 1 (2024) %u00b7 pp. 21-44